Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01082926CT.gov Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Meningioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Therapeutic Allogeneic Lymphocytes (this asset) | City of Hope Medical Center | P1 | CC · 47 |
| Cyclophosphamide | Essen Biotech | P2 | B |
| Fludarabine | Essen Biotech | P2 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Anti-Ny Eso-1 Mtcr Pbl | National Cancer Institute (NCI) | P2 | B |
| Rvp-001 | Reveal Pharmaceuticals Inc. | P2 | B |
| (S)-(-)-Perillyl Alcohol | Neonc Technologies, Inc. | P2 | CCC |
| TIL | Essen Biotech | P1/2 | CC |
| Pioglitazone | Wake Forest University Health Sciences | P1 | CC |
+11 more in the Meningioma cohort
Other indications for Therapeutic Allogeneic Lymphocytes
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Myeloid Leukemia | — | P2 | BBB · 72 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2 | BB · 70 |
| Plasma Cell Myeloma | — | P2 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Therapeutic Allogeneic Lymphocytes in Meningioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/therapeutic-allogeneic-lymphocytes-meningioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →